1NWS
VKTX icon

1 North Wealth Services’s Viking Therapeutics VKTX Stock Holding History

1 North Wealth Services’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Hold
400
– – 0.01% 152
2026
Q1 		$13K Buy
+400
New +$12.9K ﹤0.01% 147

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

1 North Wealth Services's VKTX Position: Q2 2026 in Review

1 North Wealth Services held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 400 shares worth $15.6K. The position accounts for 0.01% of the portfolio, ranked #152.

1 North Wealth Services first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • 1 North Wealth Services held 400 shares of Viking Therapeutics worth $15.6K as of Q2 2026.
  • 1 North Wealth Services left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.01% of 1 North Wealth Services's portfolio in Q2 2026, its #152 holding.
  • 1 North Wealth Services first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on 1 North Wealth Services's 13F filing for Q2 2026, filed 3 Aug 2026.